REFERENCES
- Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007;13:411–6.
- Brashear A. Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics. 2009;3:1–7.
- Crowner BE. Cervical dystonia: Disease profile and clinical management. Phys Ther. 2007;87:1511–26.
- Ben-Shlomo Y, Camfield L, Warner T. What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry. 2002;72:608–14.
- Cloud LJ, Jinnah HA. Treatment strategies for dystonia. Expert Opin Pharmacother. 2010;11:5–15.
- Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011;18(1):5–18.
- Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20:783–91.
- Wissel J, Kanovsky P, Ruzicka E, Bares M, Hortova H, Streitova H, Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: Results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol. 2001;248:1073–8.
- Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998;64:13–7.
- Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16:316–23.
- Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res. 2009;31:463–6.
- Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1699–706.
- Camargo CH, Teive HA, Becker N, Baran MH, Scola RH, Werneck LC. Cervical dystonia: Clinical and therapeutic features in 85 patients. Arq Neuropsiquiatr. 2008;66:15–21.